276862-76-1

Basic information

• Product Name: (3S,4S)-Pyrrolidine-3,4-diol hydrochloride
• Synonyms: (3s,4s)-pyrrolidine-3,4-diol hydrochloride;(3S,4S)-3,4-Dihydroxypyrrolidine hydrochloride;(3S,4S)-3,4-Pyrrolidinediol hydrochloride;3,4-Pyrrolidinediol, hydrochloride, (3S,4S)-;EOS-62446;(3S,4S)-PYRROLIDINE-3,4-DIOL HCL
• CAS NO: 276862-76-1
• Molecular Formula: C₄H₉NO₂*ClH
• Molecular Weight: 139.58
• Mol File: 276862-76-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (3S,4S)-Pyrrolidine-3,4-diol hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4S)-Pyrrolidine-3,4-diol hydrochloride(276862-76-1)
• EPA Substance Registry System: (3S,4S)-Pyrrolidine-3,4-diol hydrochloride(276862-76-1)

Safety Data

• Hazardous Substances Data: 276862-76-1(Hazardous Substances Data)

Usage

General Description

(3S,4S)-Pyrrolidine-3,4-diol hydrochloride is a chemical compound with the molecular formula C4H10NO2Cl. It is a derivative of the amino acid proline and is commonly used in organic synthesis and chemical research. (3S,4S)-Pyrrolidine-3,4-diol hydrochloride is a white crystalline powder that is soluble in water and has a molecular weight of 136.57 g/mol. It is known to exhibit antioxidant and anti-inflammatory properties, and it has been studied for its potential therapeutic applications in various diseases such as cancer, diabetes, and cardiovascular disorders. Additionally, (3S,4S)-Pyrrolidine-3,4-diol hydrochloride is also used as a chiral auxiliary in asymmetric synthesis and may also have potential applications in the development of pharmaceuticals and biologically active compounds.

InChI:InChI=1/C4H9NO2.ClH/c6-3-1-5-2-4(3)7;/h3-7H,1-2H2;1H/t3-,4-;/m0./s1

Upstream product

• 90365-74-5 (3S,4S)-(+)-1-benzyl-3,4-pyrrolidinediol 
• 150986-62-2 S,S-3,4-dihydroxypyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1255303-61-7 {4-[2-((3S,4S)-3,4-Dihydroxypyrrolidin-1-yl)ethoxy]pyridin-2-yl}-{3-[4-(4-ethylbenzyloxy)-3-methoxyphenyl]azetidin-1-yl}-methanone 

Relevant articles and documents

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases

Adenosine is known to be released under a variety of physiological and pathophysiological conditions to facilitate the protection and regeneration of injured ischemic tissues. The activation of myocardial adenosine A1 receptors (A1Rs) has been shown to inhibit myocardial pathologies associated with ischemia and reperfusion injury, suggesting several options for new cardiovascular therapies. When full A1R agonists are used, the desired protective and regenerative cardiovascular effects are usually overshadowed by unintended pharmacological effects such as induction of bradycardia, atrioventricular (AV) blocks, and sedation. These unwanted effects can be overcome by using partial A1R agonists. Starting from previously reported capadenoson we evaluated options to tailor A1R agonists to a specific partiality range, thereby optimizing the therapeutic window. This led to the identification of the potent and selective agonist neladenoson, which shows the desired partial response on the A1R, resulting in cardioprotection without sedative effects or cardiac AV blocks. To circumvent solubility and formulation issues for neladenoson, a prodrug approach was pursued. The dipeptide ester neladenoson bialanate hydrochloride showed significantly improved solubility and exposure after oral administration. Neladenoson bialanate hydrochloride is currently being evaluated in clinical trials for the treatment of heart failure.

GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.